Wechselwirkungen · Mayzent
Mayzent 0.25 mg film-coated tablets Mayzent 1 mg film-coated tablets Mayzent 2 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-140776 · Präparat HOS-098578
During and for up to 4 weeks after treatment with siponimod vaccinations may be less effective. The efficacy of vaccination is not considered to be compromised if siponimod treatment is paused 1 week prior to vaccination until 4 weeks after vaccination. In a dedicated phase I healthy volunteer study, concomitant siponimod treatment with influenza vaccines or shorter treatment pause (from 10 days prior to 14 days after vaccination) showed inferior responder rates (approximately 15% to 30% lower) compared to placebo, while the efficacy of a PPV 23 vaccination was not compromised by concomitant siponimod treatment (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): placebo (HOS-088378) siponimod (HOS-140758)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-30T13:30:00Z · SHA-256 b62239a9c4a22d1f94cd1536a5e3508a96429fc578f584f957a09a5d7c9c030b · Passage 9fe3fb95ce76a5f18260b78dcc242b00c64e38dbcf6176ca52446b2d5731b760 · Zeichen 2906–3543 im Abschnitt